Trends Mol Med 22:359376 Finan B, Yang B, Ottaway N et al (2015) A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Cardiologists have aggressively treated dyslipidemia, hypertension, and smoking but have somewhat neglected diabetes
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
(2007) study measured the countereffect directly
Common side effects (10% incidence) observed in trials included injection-site reactions (redness, pain), headache, diarrhea, and fatigue [pubmed.ncbi.nlm.nih.gov]
The participants given liraglutide lost more weight than did those on placebo, up to 7.2 kg compared to 2.8 kg with life-style placebo, and compared to 2.1 kg with orlistat